SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CureVac N.V. (CVAC) trades at a trailing P/E of 6.5. Trailing earnings yield is 15.46%.
Criteria proven by this page:
- VALUE (78/100, Pass) — P/E is below market average (6.5); earnings yield beats bond yields (15.46%).
- Trailing Earnings Yield 15.46% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $5.00 (+7.3% upside) — modest upside expected.
Overall SharesGrow Score: 73/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
78/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CVAC
Valuation Multiples
P/E (TTM)6.5
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.96
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.72
Book Value / Share$0.00
Revenue / Share$2.38
FCF / Share$0.00
Yields & Fair Value
Earnings Yield15.46%
Dividend Yield0.00%
Analyst Target$5.00 (+7.3%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.40 |
$12.87M |
$-71.24M |
-553.5% |
| 2019 |
$-0.53 |
$17.42M |
$-99.87M |
-573.5% |
| 2020 |
$-0.98 |
$48.9M |
$-129.07M |
-264% |
| 2021 |
$-2.21 |
$102.99M |
$-411.72M |
-399.8% |
| 2022 |
$-1.32 |
$67.42M |
$-249.03M |
-369.4% |
| 2023 |
$-1.18 |
$53.76M |
$-260.17M |
-484% |
| 2024 |
$0.72 |
$535.18M |
$162.19M |
30.3% |
